Ana Jagodić

Dr. Ana Jagodić

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AKAntea Krsek
Antea Krsek
LSLou Marie Salomé Schleicher
Lou Marie Salomé Schleicher
AJAna Jagodić
Ana Jagodić
LBLara Baticic
Lara Baticic
Chronic inflammation plays a crucial role in the pathogenesis and progression of neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), where sustained neuroinflammatory responses contribute to neuronal damage and functional decline. Recent advances in nanomedicine offer novel therapeutic strategies aimed at modulating inflammation, with a focus on targeting the gut–brain axis, a key mediator in the interplay between systemic inflammation and neurodegeneration. Artificial intelligence (AI) has emerged as a transformative tool in this context, facilitating the integration of large, complex datasets to better understand the intricate relationship between gut microbiota dysbiosis, chronic neuroinflammation, the exposome (cumulative impact of lifelong environmental exposures), and disease manifestation. AI-driven approaches and integrating exposome data with AI enable deeper insights into exposure–microbiome–inflammation interactions, enhance our understanding of the inflammatory pathways involved, support the development of predictive models for disease progression, and optimize the delivery of nanomedicine-based therapeutics. Additionally, AI applications in neuroimaging and personalized therapy planning have shown promise in addressing both motor and non-motor symptoms. This review provides a comprehensive synthesis of current knowledge, highlighting the convergence of AI, nanomedicine, and chronic inflammation in neurodegenerative disease care.

Verified
Journal Article
Open access
PDF file
AJAna Jagodić
Ana Jagodić
DZDorotea Zivalj
Dorotea Zivalj
AKAntea Krsek
Antea Krsek
LBLara Baticic
Lara Baticic
Ischemic stroke is a complex, multifactorial disorder with a significant heritable component. Recent developments in genome-wide association studies (GWASs) have identified several common variants associated with clinical outcomes, stroke subtypes, and overall risk. Key loci implicated in biological pathways related to vascular integrity, lipid metabolism, inflammation, and atherogenesis include 9p21 (ANRIL), HDAC9, SORT1, and PITX2. Although polygenic risk scores (PRSs) hold promise for early risk prediction and stratification, their clinical utility remains limited by Eurocentric bias and missing heritability. Integrating multiomics approaches, such as functional genomics, transcriptomics, and epigenomics, enhances our understanding of stroke pathophysiology and paves the way for precision medicine. This review summarizes the current genetic landscape of ischemic stroke, emphasizing how evolving methodologies are shaping its prevention, diagnosis, and treatment.

2 April 2025 in Gastrointestinal Disorders
Verified
Journal Article
Open access
PDF file
AJAna Jagodić
Ana Jagodić
AKAntea Krsek
Antea Krsek
LSLou Marie Salomé Schleicher
Lou Marie Salomé Schleicher
LBLara Baticic
Lara Baticic
Microbiome dysbiosis—an imbalance in gut microbial communities—has emerged as a critical factor in the pathogenesis of neurological disorders, particularly Alzheimer’s and Parkinson’s diseases. This review examines the role of gut microbiota in neurodegeneration, emphasizing how dysbiosis disrupts gut–brain communication through mechanisms such as impaired gut permeability, systemic inflammation, and neuroinflammation. The gastrointestinal and central nervous systems interact bidirectionally, with microbial metabolites like short-chain fatty acids playing a pivotal role in maintaining gut and brain health. Dysbiotic shifts in microbial composition can compromise the blood–brain barrier, enabling inflammatory molecules to alter brain biochemistry and potentially accelerate neurodegenerative processes. Additionally, this review explores therapeutic strategies—including probiotics, prebiotics, and dietary modifications—designed to restore microbial balance, reduce neuroinflammation, and slow disease progression. Further research is essential to refine microbiome-targeted therapies and fully elucidate their potential in managing neurodegenerative diseases.